- Home
- NNBR vs CRBP Comparison
NNBR vs CRBP Comparison
Compare NNBR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- CRBP
- Stock Information
- Founded
- NNBR 1980
- CRBP 2009
- Country
- NNBR United States
- CRBP United States
- Employees
- NNBR N/A
- CRBP N/A
- Industry
- NNBR Industrial Machinery/Components
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- NNBR Industrials
- CRBP Health Care
- Exchange
- NNBR Nasdaq
- CRBP Nasdaq
- Market Cap
- NNBR 129.3M
- CRBP 114.8M
- IPO Year
- NNBR 1994
- CRBP N/A
- Fundamental
- Price
- NNBR $2.51
- CRBP $9.89
- Analyst Decision
- NNBR
- CRBP Strong Buy
- Analyst Count
- NNBR 0
- CRBP 10
- Target Price
- NNBR N/A
- CRBP $53.22
- AVG Volume (30 Days)
- NNBR 72.7K
- CRBP 97.4K
- Earning Date
- NNBR 10-29-2025
- CRBP 11-06-2025
- Dividend Yield
- NNBR N/A
- CRBP N/A
- EPS Growth
- NNBR N/A
- CRBP N/A
- EPS
- NNBR N/A
- CRBP N/A
- Revenue
- NNBR $433,709,000.00
- CRBP N/A
- Revenue This Year
- NNBR N/A
- CRBP N/A
- Revenue Next Year
- NNBR $4.88
- CRBP $220.04
- P/E Ratio
- NNBR N/A
- CRBP N/A
- Revenue Growth
- NNBR N/A
- CRBP N/A
- 52 Week Low
- NNBR $1.58
- CRBP $4.64
- 52 Week High
- NNBR $4.67
- CRBP $56.93
- Technical
- Relative Strength Index (RSI)
- NNBR 57.36
- CRBP 56.38
- Support Level
- NNBR $2.41
- CRBP $9.50
- Resistance Level
- NNBR $2.63
- CRBP $10.17
- Average True Range (ATR)
- NNBR 0.13
- CRBP 0.59
- MACD
- NNBR 0.00
- CRBP -0.02
- Stochastic Oscillator
- NNBR 69.23
- CRBP 56.74
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.